2-4 In addition, a randomized trial of sarilumab, another interleukin-6 receptor monoclonal antibody, showed a trend toward lower mortality among critically ill patients. 6 Two randomized, open-label trials exploring the use of tocilizumab in patients receiving supplemental oxygen without noninvasive or invasive mechanical ventilation were recently published. 8 , 9 In one, tocilizumab treatment appeared to reduce the need for mechanical or noninvasive ventilation or death by day 14. 8 It should be noted that dexamethasone was used more frequently in the control group than in the tocilizumab group, which may have mitigated the treatment effect.
1
—
—